Combating inconsistent evaluation of intra-tumor immune status by a novel transcriptomic signature in hepatocellular carcinoma

Article Gastroenterology & Hepatology

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Carla Montironi et al.

Summary: This study characterizes the immunogenomic contexture of hepatocellular carcinoma (HCC) and defines inflamed and non-inflamed tumors. Two distinct patterns of CTNNB1 are associated with differential immune evasion and may help predict immune response in HCC.

GUT (2023)

Add to Collection

Review Oncology

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally. Traditional treatments involve specific drugs, but the emergence of immune checkpoint inhibitors has revolutionized the management of HCC.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Cellular heterogeneity and plasticity in liver cancer

Lo -Kong Chan et al.

Summary: Hepatocarcinogenesis involves complex genetic and cellular dysregulations. Next-generation sequencing technologies provide new insight into the heterogeneity of hepatocellular carcinoma (HCC) and guide the development and use of targeted therapy and immunotherapy. Liquid biopsy coupled with high-sensitivity sequencing could be a practical and safer approach to detect tumor heterogeneity in HCC patients.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Genetics & Heredity

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Jung Yong Hong et al.

Summary: This study comprehensively characterized the genomic properties of hepatocellular carcinoma (HCC) patients in response to pembrolizumab treatment. It identified that the infiltration of cytotoxic T cells, increased active circulating CD8+ T cells, and down-regulation of neutrophil-associated markers significantly contributed to the effectiveness of pembrolizumab therapy. Female gender, PD-L1 positivity, and low neutrophil-to-lymphocyte ratio (NLR) were also identified as contributing factors to pembrolizumab response.

GENOME MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma

Phuong H. D. Nguyen et al.

Summary: The study reveals significant immune intratumoural heterogeneity in hepatocellular carcinomas, which is closely associated with tumor evolution and poor clinical outcomes. Tumors with high immune heterogeneity demonstrate an immune suppressive microenvironment, indicating a complex interplay between tumor and immune system during disease progression.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Gastroenterology & Hepatology